- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: Margenza® | margetuximab-cmkb | MGAH-22
margetuximab is an approved drug (FDA (2020))
Compound class: Antibody
Comment: Margetuximab is a chimeric monoclonal antibody targeting epidermal growth factor receptor 2 (ERBB2).
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. Peptide sequence search of patented sequences reveals a 100% match between the heavy chain variable domain of margetuximab and SEQ ID NO: 13 from patent US8802093 B2, and antibody clone ch4D5-FcMT3 . Although the patent describes performing Biacore assays to determine antibody-target (ERBB2) affinity, a KD value is not provided.
|Approved drug?||Yes (FDA (2020))|
|International Nonproprietary Names|
|Margenza® | margetuximab-cmkb | MGAH-22|
|GtoPdb PubChem SID||252166886|
|Search PubMed clinical trials||margetuximab|
|Search PubMed titles||margetuximab|
|Search PubMed titles/abstracts||margetuximab|